Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials

Elmakaty, Ibrahim; Abdo, Ruba; Elsabagh, Ahmed; Elsayed, Abdelrahman; Malki, Mohammed Imad

doi:10.1186/s12935-023-02941-7

Table 1 Characteristics of included trials

From: Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials

Trial	NCT	First author	Year	Phase	No. of TNBC patients	Median age	Cancer stage	ICI used	Treatment arm	Control arm	Dose of ICI used	Duration of ICI used	Median follow-up time	PD-L1 expression positivity
SAFIR02-BREAST [38]	NCT02299999	Bachelot	2021	II	82	56 years	Metastatic treated TNBC for maintenance	Durvalumab	Durvalumab	Continuation of induction Chemotherapy	10 mg/kg q2wk	7 cycles	19.7 months	52%
KEYNOTE-355 [35]	NCT02819518	Cortes	2020	III	847	53.5 years	Untreated locally recurrent inoperable or metastatic TNBC	Pembrolizumab	Pembrolizumab + Investigator’s choice chemotherapy	Placebo + Investigator’s choice chemotherapy	200 mg q3wk	Up to 35 administrations or disease progression	26 months	75%
Garrido-Castro [43]	NCT03414684	Garrido-Castro	2022	II	78	59.1 years	Metastatic TNBC	Nivolumab	Nivolumab + Carboplatin	Carboplatin	360 mg IV q3wk	Not mentioned	23.5 months	39%
NeoTRIPaPDL1 [36]	NCT02620280	Gianni	2022	III	280	50 years	Invasive TNBC	Atezolizumab	Atezolizumab + Carboplatin + Nab-paclitaxel	Carboplatin + Nab-paclitaxel	1200 mg IV q3wk	8 cycles	On-going	56%
GeparNuevo [37]	NCT02685059	Loibl	2022	II	174	49.5 years	Primary, non-metastatic invasive TNBC	Durvalumab	Durvalumab + Nab-paclitaxel then epirubicin/cyclophosphamide	Placebo + Nab-paclitaxel then epirubicin/cyclophosphamide	First dose 0.75 g then 1.5 g q4wk	6 cycles	43.7 months	87%
IMpassion131 [33]	NCT03125902	Miles	2021	III	651	54 years	Unresectable locally or metastatic TNBC	Atezolizumab	Atezolizumab + Paclitaxel	Placebo + Paclitaxel	840 mg day 1,15 q4wk	6 cycles	14.5 months	45%
IMpassion031 [39]	NCT03197935	Mittendorf	2020	III	333	51 years	Early-stage TNBC	Atezolizumab	Atezolizumab + Nab-paclitaxel/Doxorubicin/Cyclophosphamide	Placebo + Nab-paclitaxel + Doxorubicin/Cyclophosphamide	840 mg IV q2wk	6 cycles	20 months	46%
IMpassion130 [40]	NCT02425891	Schmid	2022	III	902	55 years	Advanced TNBC	Atezolizumab	Atezolizumab + Nab-paclitaxel	Placebo + Nab-paclitaxel	840 mg day 1,15 q4wk	6 cycles	12.9 months	41%
Nci 10,013 [44]	NCT02883062	Ademuyiwa	2021	II	67	52 years	Stage II-III TNBC	Atezolizumab	Carboplatin + Paclitaxel	Atezolizumab + Carboplatin + Paclitaxel	1200 mg q3wk	4 cycles	6 months	Not done yet
KEYNOTE-522 [41]	NCT03036488	Schmid	2020	III	1174	48–49 years	Primary, non-metastatic TNBC (Stage II and III)	Pembrolizumab	Pembrolizumab + Paclitaxel/Carboplatin + Doxorubicin OR Epirubicin/Cyclophosphamide	Placebo + Paclitaxel/Carboplatin + Doxorubicin OR Epirubicin/Cyclophosphamide	200 mg IV q3wk	Neoadjuvant up to 8 cycles	15.5 months	84%
KEYNOTE-119 [34]	NCT02555657	Winer	2021	III	622	52 years	Metastatic treated TNBC	Pembrolizumab	Pembrolizumab	Investigator’s choice mono-chemotherapy	200 mg IV q3wk	Up to 35 administrations	31.5 months	65%
I-SPY2 Trial [42]	NCT01042379	Nanda	2020	II	114	50 years	Stage II-III TNBC	Pembrolizumab	Pembrolizumab + Paclitaxel + Doxorubicin/Cyclophosphamide	Paclitaxel + Doxorubicin/Cyclophosphamide	200 mg IV q3wk	4 cycles	3 yrs	Not done yet

NCT National Clinical Trial; TNBC Triple Negative Breast Cancer; ICI Immune Checkpoint Inhibitor; PD-L1, Programmed Cell Death Ligand 1; q2wk. once every 2 weeks; q3wk. once every 3 weeks; q4wk. once every 4 weeks

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com

Cancer Cell International

Contact us